Back to News
Market Impact: 0.35
Tango Therapeutics Maps 2027 Phase 3 Trial After Promising Cancer Data;Stock Down In Pre-Market
Source: Nasdaq
Healthcare & Biotech
Tango Therapeutics reported updated Phase 1/2 results showing an 82% objective response rate for investigational vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitor daraxonrasib. The reported patients had previously treated MTAP-deleted cancer; the provided article text is truncated, so it gives no further details on the patient group or study results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
RVMD0.25
TNGX0.70
More News
- Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal